View in EDS HTML Full Text PDF Full Text

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

Saved in:
Bibliographic Details
Title: Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Authors: Packer, Milton1,2 (AUTHOR) milton.packer@baylorhealth.edu, Butler, Javed3 (AUTHOR), Filippatos, Gerasimos S.4,5 (AUTHOR), Jamal, Waheed6 (AUTHOR), Salsali, Afshin7 (AUTHOR), Schnee, Janet7 (AUTHOR), Kimura, Karen8 (AUTHOR), Zeller, Cordula9 (AUTHOR), George, Jyothis6 (AUTHOR), Brueckmann, Martina6,10 (AUTHOR), Anker, Stefan D.11 (AUTHOR), Zannad, Faiez12 (AUTHOR), Filippatos, Gerasimos (AUTHOR), Perrone, Sergio (AUTHOR), Nicholls, Stephen (AUTHOR), Janssens, Stefan (AUTHOR), Bocchi, Edmar (AUTHOR), Giannetti, Nadia (AUTHOR), Verma, Subodh (AUTHOR), Jian, Zhang (AUTHOR)
Source: European Journal of Heart Failure. Oct2019, Vol. 21 Issue 10, p1270-1278. 9p. 1 Diagram, 1 Chart.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13889842
DOI:10.1002/ejhf.1536